In agreement with this, mutations in SUZ12, a component of EZH2-containing polycomb repressor complex 2 (PRC2), which inhibits CXXC4 expression,22 have been detected in the SCN-AML patient used for this study and others.6 This evidence concerns the gene CXXC4 and acute myeloid leukemia.